

Ref: FOI/GS/ID 6404

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

16 December 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to anti-VEFG treatments for eye conditions.

You asked:

1. Within your trust how many patients over the last 12 months (November 2019 to October 2020 or latest available) have received the following anti-VEGF treatments:

- *Aflibercept*
- *Bevacizumab*
- *Brolucizumab*
- *Dexamethasone*
- *Fluocinolone acetonide*
- *Ranibizumab*

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

- *Aflibercept*
- *Bevacizumab*
- *Brolucizumab*
- *Dexamethasone*
- *Fluocinolone acetonide*
- *Ranibizumab*

Trust response:

	Total patients	New Patients
Aflibercept	1336	438
Bevacizumab	146	Data not available for this cohort
Dexamethasone	179	130

Fluocinolone Acetonide	6	4
Ranibizumab	884	216

Last 12 months including 11/2020.

Brolucizumab, does not have NICE approval yet and therefore not dispensed at the Trust.